Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 6/20 | 0.49 |
| ▸ | ADA | P00813 | 1/20 | 0.46 |
| ▸ | PRMT5 | O14744 | 4/20 | 0.42 |
| ▸ | WDR77 | Q9BQA1 | 4/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13650033 | 0.88 | ADORA2A (0.47) | ADORA2AADAADORA3PDE4DPDE3A | |
| SCHEMBL474846 | 0.87 | ADORA2A (0.53) | ADORA2AADAPRMT5WDR77ADORA3 | |
| SCHEMBL12031227 | 0.87 | ADORA2A (0.53) | ADORA2AADAPRMT5WDR77ADORA3 | |
| SCHEMBL12154572 | 0.87 | ADORA2A (0.53) | ADORA2AADAPRMT5WDR77ADORA3 | |
| SCHEMBL12150880 | 0.87 | ADORA2A (0.53) | ADORA2AADAPRMT5WDR77ADORA3 | |
| SCHEMBL10208056 | 0.86 | ADORA2A (0.52) | ADORA2AADAPRMT5WDR77ADORA3 | |
| SCHEMBL730785 | 0.85 | ADORA2A (0.51) | ADORA2AADAPRMT5WDR77ADORA3 | |
| SCHEMBL12447020 | 0.85 | ADORA2A (0.51) | ADORA2AADAPRMT5WDR77ADORA3 | |
| SCHEMBL6380424 | 0.83 | ADORA2A (0.43) | ADORA2AADAPRMT5WDR77ADORA3 | |
| Beta-2'-C-Methyl-7-Deaza-Adenosine SCHEMBL733423 | 0.81 | ADORA2A (0.67) | ADORA2AADAPRMT5WDR77ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253648-A1 | Tricyclic-Nucleoside Compounds for Treating Viral Infections | SMITHKLINE BEECHAM CORPORATION (US) | 2009-10-08 | — | — | US | disclosed |
| US-20090208457-A1 | Tricyclic-Nucleoside Prodrugs for Treating Viral Infections | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-20 | — | — | US | disclosed |
| US-7534771-B2 | Tricyclic-nucleoside prodrugs for treating viral infections | SMITHKLINE BEECHAM CORPORATION (US) | 2009-05-19 | — | — | US | disclosed |
| US-7524825-B2 | Tricyclic-nucleoside compounds for treating viral infections | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-28 | — | — | US | disclosed |
| US-20090048189-A1 | TRICYCLIC-NUCLEOSIDE COMPOUNDS FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048189-A1 | TRICYCLIC-NUCLEOSIDE COMPOUNDS FOR TREATING VIRAL INFECTIONS | TYMP, PNP, NSUN2 | ADORA2A 334/4885ADA 62/4885PRMT5 2728/4885 |
| US-20090208457-A1 | Tricyclic-Nucleoside Prodrugs for Treating Viral Infections | PNP, TYMP, HAVCR2 | ADORA2A 172/4885ADA 16/4885PRMT5 3741/4885 |
| US-20090253648-A1 | Tricyclic-Nucleoside Compounds for Treating Viral Infections | PNP, TYMP, NSUN2 | ADORA2A 145/4885ADA 31/4885PRMT5 3135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.